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ABSTRACT
Objective To assess the potential performance of screen-
ing for fetal trisomies 21, 18 and 13 by cell-free
DNA (cfDNA) analysis of maternal blood using the
IONA® test.
Methods This was a nested case–control study of cfDNA
analysis of maternal plasma using the IONA test. Samples
were obtained at 11–13weeks’ gestation, before chorionic
villus sampling, from 201 euploid pregnancies, 35 with
trisomy 21, four with trisomy 18 and twowith trisomy 13.
Laboratory personnel were blinded to the fetal karyotype.
Results Probability scores for trisomies 21, 18 and 13
were given for 241/242 samples analyzed. No probability
score was provided for one (0.5%) euploid pregnancy
because of low fetal fraction. In all 35 cases of trisomy
21 the probability score for trisomy 21 was> 95% and
the scores for trisomies 18 and 13 were≤ 0.0001%. In
all four cases of trisomy 18, the probability score for
trisomy 18 was>77% and the scores for trisomies 21
and 13 were≤ 0.0001%. In the two cases of trisomy 13,
the probability score for trisomy 13 was> 59% and the
scores for trisomies 21 and 18were≤ 0.0001%. In the 200
euploid pregnancies with a test result, the probability score
was< 0.08% for trisomy 21, < 0.001% for trisomy 18
and<0.002% for trisomy 13. Therefore, the IONA test
detected 100% of all three trisomies, with a false-positive
rate of 0%.
Conclusion The IONA test successfully differentiated all
cases of trisomies 21, 18 and 13 from euploid pregnancies.
© 2015 The Authors. Ultrasound in Obstetrics &
Gynecology published by John Wiley & Sons Ltd on
behalf of the International Society of Ultrasound in
Obstetrics and Gynecology.
INTRODUCTION
Diagnosis of fetal aneuploidy relies on invasive testing
by chorionic villus sampling (CVS) or amniocentesis in
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pregnancies that are identified by screening to be at
high risk for such aneuploidies1. In many developed
countries the most widely accepted method of screening at
present is one that is based on a combination of maternal
age, fetal nuchal translucency (NT) thickness, maternal
serum free beta-human chorionic gonadotropin (β-hCG)
and pregnancy-associated plasma protein-A (PAPP-A),
that could identify approximately 90% of fetuses with
trisomies 21, 18 or 13 at a false-positive rate (FPR)
of 5%2. A new method of screening for fetal trisomy
relies on the examination of cell-free DNA (cfDNA) in
maternal plasma3. Several studies in the last 4 years have
reported the clinical validation and/or implementation
of cfDNA testing and a recent meta-analysis of such
studies weighted pooled detection rates (DR) and FPR in
singleton pregnancies as 99.2% and 0.09%, respectively,
for trisomy 21, 96.3% and 0.13% for trisomy 18, and
91.0% and 0.13% for trisomy 134.
The IONA® test and IONA software (Premaitha Health
plc, Manchester, UK) is a cfDNA test developed recently
which uses the Ion Proton™ sequencing platform (Thermo
Fisher Scientific, Waltham, MA, USA) and an algorithm
that determines the relative number of chromosomal
copies, enabling the detection of fetal trisomies5. The
objective of this study was to assess the potential perfor-
mance of the IONA test and IONA software in screening
for trisomies 21, 18 and 13 at 11–13 weeks’ gestation.
METHODS
This was a nested case–control study of stored maternal
plasma from 242 singleton pregnancies at 11–13 weeks’
gestation, including 201 with euploid fetuses, 35 with
trisomy 21, four with trisomy 18 and two with trisomy
13. In all cases fetal karyotyping was performed following
CVS in our tertiary referral center because screening by the
combined test had demonstrated an increased risk for tri-
somies 21, 18 or 13. Gestational age was determined from
the measurement of fetal crown–rump length (CRL)6.
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Maternal venous blood (10 mL) was collected before
CVS in ethylenediaminetetraacetic acid vacutainer tubes
(Becton Dickinson UK Limited, Oxfordshire, UK) and
was processed within 15 min of collection. Samples were
centrifuged at 2000 g for 10 min to separate the plasma
from packed cells and buffy coat (plasma 1) and again
at 16 000 g for 10 min to further separate cell debris
(plasma 2). Plasma 1 and 2 (2 mL each) were
divided into 0.5-mL aliquots in separate Eppendorf
tubes that were labeled with a unique patient iden-
tifier and stored at –80◦C until subsequent analy-
sis. Written informed consent was obtained from the
women who agreed to participate in the study, which
was approved by the King’s College Hospital Ethics
Committee.
We searched our database and selected 35 consecutive
cases of trisomy 21, four cases of trisomy 18 and two cases
of trisomy 13 that had 2 mL of stored plasma 2 available.
Two hundred and one euploid control subjects were
selected; none of their samples was previously thawed
and refrozen. Maternal blood was collected between April
2007 and June 2012.
Laboratory analysis
Plasma samples (four tubes of 0.5 mL per patient) from
selected cases were sent from London to the laboratory of
Premaitha Health plc in Manchester, UK. The following
information was provided to Premaitha for each case:
patient-unique identifier, maternal age, weight and height,
racial origin, method of conception, smoking habit,
gestational age in weeks, fetal CRL, and date of blood
collection. Before evaluation for fetal trisomy, Premaitha
assessed each sample for volume, adequacy of labeling,
and risk of contamination or sample mixing and informed
us that all samples met their acceptance criteria. The
242 samples were then analyzed using the IONA® test5.
Results were provided for the risk of trisomies 21, 18
and 13 in each case and the correlation between the assay
results and the fetal karyotype was determined.
Statistical analysis
Descriptive statistics are presented as median (interquar-
tile range (IQR)) for continuous variables and n (%)
for categorical variables. Probability scores for each tri-
somy are presented in scatterplots. DR and FPR are
reported based on a predefined cut-off for probability. An
age-adjusted probability of trisomy calculated to be ≥ 1
in 150 was considered a positive result, as used in the
UK National Health Service (NHS)7. Point estimates with
95% CI have been provided.
RESULTS
All 242 samples were processed with the IONA test,
however, one of these did not meet the validity criteria
applied by the IONA software owing to to a low fetal
fraction and was excluded from subsequent analysis. In
this case, sampling was performed at 13 weeks’ gestation,
the maternal weight was 86 kg and the serum PAPP-A
multiples of the median (MoM) value was 1.316 and
there were no obvious reasons for why the fetal fraction
was low. Results were generated by the IONA software
for the remaining 241 samples.
The characteristics of the euploid and aneuploid
pregnancies are summarized in Table 1. In all 35 cases
of trisomy 21, the probability score for trisomy 21
Table 1 Characteristics of study population of women with a singleton pregnancy who underwent cell-free DNA analysis using the IONA®
test, grouped according to karyotype obtained following chorionic villus sampling
Euploid Trisomy 21 Trisomy 18 Trisomy 13
Characteristic (n = 200) (n = 35) (n =4) (n = 2)
Maternal age (years) 32.9 (29.2–36.9) 38.0 (35.5–40.5) 37.7 (30.0–40.1) 32.1 (31.3–32.1)
Maternal weight (kg) 67.0 (60.0–76.0) 63.6 (57.2–74.5) 68.5 (60.9–72.0) 53.6 (50.8–53.6)
Maternal height (cm) 165 (160–170) 165 (160–167) 172 (166–173) 163 (162–163)
GA at testing (weeks) 12.7 (12.2–13.1) 13.0 (12.4–13.6) 11.9 (11.4–13.3) 12.8 (12.0–12.8)
Racial origin
Caucasian 146 (73.0) 31 (88.6) 2 (50.0) 2 (100.0)
Afro-Caribbean 38 (19.0) 1 (2.9) 1 (25.0) 0 (0)
South Asian 5 (2.5) 3 (8.6) 0 (0) 0 (0)
East Asian 3 (1.5) 0 (0) 0 (0) 0 (0)
Mixed 8 (4.0) 0 (0) 1 (25.0) 0 (0)
Cigarette smoker 10 (5.0) 3 (8.6) 1 (25.0) 0 (0)
Mode of conception
Spontaneous 189 (94.5) 33 (94.3) 2 (50.0) 2 (100.0)
Ovulation drugs 2 (1.0) 2 (5.7) 0 (0) 0 (0)
In-vitro fertilization 9 (4.5) 0 (0) 2 (50.0) 0 (0)
Fetal NT (mm) 1.8 (1.5–2.2) 4.2 (3.1–5.3) 2.5 (1.6–6.8) 5.9 (2.8–5.9)
Free β-hCG MoM 1.232 (0.821–1.950) 2.551 (1.696–3.615) 0.352 (0.224–0.901) 1.136 (0.515–1.136)
PAPP-A MoM 1.144 (0.736–1.612) 0.708 (0.500–1.157) 0.232 (0.145–0.288) 0.621 (0.146–0.621)
Data are given as median (interquartile range) or n (%). β-hCG, beta-human chorionic gonadotropin; GA, gestational age; MoM, multiples
of the median; NT, nuchal translucency; PAPP-A, pregnancy-associated plasma protein-A.
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2016; 47: 184–187.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
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Figure 1 Probability scores for trisomy 21 (a), trisomy 18 (b) and trisomy 13 (c) in singleton pregnancies with trisomic ( ) or euploid ( )
fetuses that underwent cell-free DNA analysis using the IONA® test.
was> 95% and the scores for trisomies 18 and 13
were ≤ 0.0001% (Figure 1). In all four cases of trisomy
18, the probability score for trisomy 18 was> 77% and
the scores for trisomies 21 and 13 were ≤ 0.0001%. In the
two cases of trisomy 13, the probability score for trisomy
13 was> 59% and the scores for trisomies 21 and 18
were ≤ 0.0001%. In the 200 euploid pregnancies with a
test result, the probability score was< 0.08% for trisomy
21, <0.001% for trisomy 18 and< 0.002% for trisomy
13. Therefore, the DR for trisomy 21 was 100% (95% CI,
90.1–100.0%; 35/35 cases), the DR for trisomy 18 was
100% (95% CI, 51.0–100.0%; 4/4 cases) and the DR
for trisomy 13 was 100% (95% CI, 34.2–100.0%; 2/2
cases), with a FPR of 0% (95% CI, 0.0–1.9%; 200/200
cases).
DISCUSSION
Main findings of the study
This nested case–control study has demonstrated that, in
pregnancies considered by the combined test to be at high
risk for trisomies 21, 18 or 13, cfDNA testing of maternal
plasma at 11–13 weeks’ gestation using the IONA test
identified correctly all trisomic pregnancies, at a FPR
of 0%.
Comparison with findings from previous studies
The performance of the IONA test in the detection of
trisomy 21 is comparable to the reported performance
of cfDNA analysis in a recent meta-analysis4. Although
the number of cases of trisomies 18 and 13 is too small
for definitive conclusions to be drawn, the performance
of the test may be higher than in other studies8–30. In
this study, compared with most previous publications on
cfDNA testing, we used samples that were obtained at
11–13 weeks exclusively. This is important because, in
the last decade, there has been a major shift from second-
to first-trimester screening and diagnosis of aneuploidies.
Strengths and limitations of the study
The study has several strengths, including a large number
of pregnancies affected by trisomy 21, laboratory staff
blinded to the fetal karyotype or outcome at the time
of cfDNA testing, and complete outcome data. The
study examined the application of a novel technique and
software. The main limitations include its retrospective
design, inclusion of only high-risk pregnancies and a
small number of pregnancies affected by trisomies 18
or 13. However, the reported performance of cfDNA
testing is similar in studies in both high- and low-risk
populations11,22,23,25,29,31–34, we therefore believe that
the results of the study can be applied to a general
population but in an ideal situation such results should be
validated in a prospective study.
Conclusion
In this study, the IONA test differentiated all cases of
trisomy 21, 18 and 13 from euploid pregnancies.
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